FDA approves pembrolizumab combinations for muscle invasive bladder cancer
MRK•FDA approval expands use of Keytruda-based combinations
The U.S. Food and Drug Administration said it approves pembrolizumab, or pembrolizumab and berahyaluronidase alfa-pmph, each with enfortumab vedotin-ejfv for muscle invasive bladder cancer.
Pembrolizumab is marketed as Keytruda by Merck.
